Ezetimibe lowers LDL by 15–20% by blocking Niemann-Pick C1-Like 1 (NPC1L1) protein in intestinal cells. The IMPROVE-IT trial confirmed a 6.4% relative risk reduction in cardiovascular events when added to simvastatin after ACS.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.